Senate Finance Committee leadership invited executives from five pharmacy benefit managers to testify before the committee at a drug pricing hearing slated for April 3.

Sens. Chuck Grassley (R-Iowa) and Ron Wyden (D-Ore.) invited Cigna, CVS Caremark and CVS Health Corporation, Humana, OptumRx and Prime Therapeutics to testify at the hearing, which will be the committee’s third on drug pricing.

“We’ve heard from pharmaceutical companies and it’s only fair that the committee has the opportunity to ask questions of other players in the health care supply chain,” Grassley and Wyden said in a joint statement. “Every part of the industry has a role to play in lowering prescription drug prices.”